Geiseler - Figure 26

Future Potential Therapeutic Targets to Reduce Synthesis and Secretion of Mucins

References

[1]

Ha EVS, Rogers DF. Novel therapies to inhibit mucus synthesis and secretion in airway hypersecretory diseases. Pharmacology 2016;97:84–100.

[20]

Galie N, Hinderliter AL,Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographical and Doppler measures in patients with pulmonary artrial hypertension. J am Coll Cardiol 2003;41(3):1380-1386.